A global, multicenter phase III trial, TROPION-Breast02, led by a senior medical oncologist and researcher from the National ...

Sofetabart mipitecan (LY4170156), an investigational folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC), elicited strong antitumor activity in patients with recurrent ...

Also from SGO: p53 reactivator active in advanced gynecologic cancers, "perfect" score in ...

GSK presents positive data for B7-H4-targeted ADC in gynaecological cancers: London, UK Tuesday, April 14, 2026, 13:00 Hrs [IST] GSK plc announced positive findings from its globa ...

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with ...

Feeling tired all the time isn’t just frustrating—it may be your body signaling that something deeper needs attention.

A phase 2 study evaluated the efficacy and safety of adding pembrolizumab to trimodal therapy as a bladder-sparing approach for muscle-invasive bladder cancer (MIBC).

During perimenopause and menopause, fluctuations in estrogen and progesterone can make the body’s stress response more ...

Struggling to find the energy to work out isn’t just about motivation—it’s often a combination of sleep, nutrition, and daily ...

Tisotumab vedotin plus carboplatin and pembrolizumab improved survival outcomes in patients with recurrent/metastatic cervical cancer.

Plus, what you can do about it.

Phase 1/2 RAINFOL™-01 data showed the combination of rinatabart sesutecan (Rina-S ®) and bevacizumab was tolerable, with no n ...